Tools

LEADER 02127cam 2200481 a 4500

001 ocm40709390;

003 OCoLC;

005 20141211185326.0;

008 990224s1998 dcu f000 0 eng d;

010 a| 99176895;

020 a| 0160578973;

035 a| (Sirsi) o40709390;

035 a| (OCoLC)40709390;

040 a| GPOc| DLCd| EREd| UtOrBLW;

042 a| lccopycat;

043 a| n-us---;

049 a| ERE#;

050 00 a| RA401.A3b| U48 1998;

074 a| 1019-A-01;

074 a| 1019-B-01 (MF);

082 00 a| 353.9/98/09732| 21;

086 0 a| Y 4.C 73.8:105-W;

088 a| Committee print 105-W (United States. Congress. House. Committee on Commerce);

245 10 a| Without reasonable assurance, financial and property management concerns at the Food and Drug Administration :b| a staff report /c| prepared for the use of the Subcommittee on Oversight and Investigations of the Committee on Commerce, U.S. House of Representatives.;

260 a| Washington :b| U.S. G.P.O. :b| For sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office,c| 1998.;

300 a| iv, 46 pages ;c| 24 cm;

336 a| text2| rdacontent;

337 a| unmediated2| rdamedia;

338 a| volume2| rdacarrier;

500 a| At head of title: 105th Congress, 2d session. Committee print.;

500 a| Distributed to some depository libraries in microfiche.;

500 a| Shipping list no.: 99-0104-P.;

500 a| "December 1998.";

500 a| "Committee print 105-W.";

610 20 a| Center for Biologics Evaluation and Research (U.S.)x| Management.=| ^A368272;

610 20 a| Center for Biologics Evaluation and Research (U.S.)x| Auditing.=| ^A368272;

610 10 a| United States.b| Food and Drug Administrationx| Management.=| ^A1253;

610 10 a| United States.b| Food and Drug Administrationx| Auditing.=| ^A1253;

994 a| C0b| ERE;

596 a| 1;

998 a| 1030544;

999 a| Y 4.C 73.8:105-Ww| SUDOCc| 1i| 30372012963820d| 6/17/2008l| JDOSm| JOYNERr| Ys| Yt| JDOSBKu| 6/5/2008x| BOOKz| JFEDDOCSo| .STAFF. 0;

Without reasonable assurance, financial and property management concerns at the Food and Drug Administration : a staff report / prepared for the use of the Subcommittee on Oversight and Investigations of the Committee on Commerce, U.S. House of Representatives.

Author/creator	United States
Format	Book
Publication Info	Washington : U.S. G.P.O. : For sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office, 1998.
Description	iv, 46 pages ; 24 cm
Subjects	Center for Biologics Evaluation and Research (U.S.)--Management. Center for Biologics Evaluation and Research (U.S.)--Auditing. United States. Food and Drug Administration--Management. United States. Food and Drug Administration--Auditing.

General note	At head of title: 105th Congress, 2d session. Committee print.
General note	Distributed to some depository libraries in microfiche.
General note	Shipping list no.: 99-0104-P.
General note	"December 1998."
General note	"Committee print 105-W."
LCCN	99176895
ISBN	0160578973
Technical rpt number	Committee print 105-W (United States. Congress. House. Committee on Commerce)
GPO item number	1019-A-01
GPO item number	1019-B-01 (MF)
Govt. docs number	Y 4.C 73.8:105-W

Without reasonable assurance, financial and property management concerns at the Food and Drug Administration : a staff report / prepared for the use of the Subcommittee on Oversight and Investigations of the Committee on Commerce, U.S. House of Representatives.

Click here for more information about this title